Equities

Jaguar Health Inc

Jaguar Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.04
  • Today's Change0.055 / 5.62%
  • Shares traded262.84k
  • 1 Year change-94.95%
  • Beta0.8948
Data delayed at least 15 minutes, as of Nov 22 2024 19:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Jaguar Health Inc has grown net income from a loss of -47.45m to a smaller loss of -41.30m despite falling revenues.
Gross margin80.10%
Net profit margin-365.71%
Operating margin-276.58%
Return on assets-73.81%
Return on equity-504.20%
Return on investment-106.50%
More ▼

Cash flow in USDView more

In 2023, Jaguar Health Inc increased its cash reserves by 18.28%, or 1.00m. Cash Flow from Financing totalled 34.23m or 350.65% of revenues. In addition the company used 33.24m for operations while cash from investing was breakeven.
Cash flow per share-9.59
Price/Cash flow per share--
Book value per share1.54
Tangible book value per share-0.2736
More ▼

Balance sheet in USDView more

Jaguar Health Inc has a Debt to Total Capital ratio of 68.02%, a lower figure than the previous year's 2,290.95%.
Current ratio1.84
Quick ratio1.36
Total debt/total equity2.06
Total debt/total capital0.6802
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.